Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > PL Interview

<< Previous

Bullboard Posts

Next >>

Comment by SABBOBCATon Mar 09, 2023 4:25pm

74 Views

Post# 35329099

RE:PL Interview

I meet with investors weekly to update them on what Thera has accomplished, what we have in the pipeline, and the quality of our science and management team

So what are you telling investors this week? Looks like they aren't happy with whatever it was, so was it the lack of accomplishment? The pipeline? Or the quality of the management team? Perhaps all of the above?

<< Previous

Bullboard Posts

Next >>

How a junior advances one of the largest undeveloped diamond projects